drugset / Trial / NCT03597503

Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment

NCT03597503

Phase 3 Terminated 41 enrolled Supernus Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study was to evaluate the effect of SPN-810 for the treatment of impulsive aggression (IA) in adolescents diagnosed with ADHD when taken in conjunction with standard ADHD treatment.

Timeline

Start
2018-07-31
Primary completion
2020-01-22
Completion
2020-01-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Molindone Small molecule